Korsana Biosciences, Inc.

Korsana Biosciences, Inc.

NNASDAQ:KRSA
32.68
USD
+1.03
(+3.25%)
1.46BMarket Cap
Mar 24Next Earn
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
-0.02
-7.07
- -
Free Cash Flow per Basic Share
0.01
-4.44
- -
Dividend per Share
- -
- -
- -
Book Value per Share
- -
-0.75
8.6
Tangible Book Value per Share
- -
-0.75
8.6
Basic Weighted Avg Shares
5
5
6
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
-36
- -
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
- -
- -
- -
Working Capital
10
142
416
LT Debt
- -
- -
1
Total Equity
- -
-34
392
Return on Invested Capital (%)
- -
- -
- -
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Sep'26
ST Debt
- -
LT Borrowings
- -
LT Finance Leases
1
Preferred Equity and Hybrid Capital
- -
Shares Outstanding
46
Market Capitalization
1,457

Working Capital

USD

•

in mil. unless spec.
Sep'26
Total Current Assets
461
Cash, Cash Equivalents & STI
456
Accounts Receivable, Net
- -
Inventories
- -
Total Current Liabilities
44
Payables & Accruals
30
ST Debt
- -
Deferred Revenue
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-51,566.67%
Free Cash Flow
- -
- -
-51,022.73%
Net Income, GAAP
- -
- -
40,402.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
-4.27
-25.09
-7.07
2026
- -
- -
-3.43
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jonathan Violin
Full Time Employees
1
Sector
Health technology
Industry
Biotechnology
Address
221 Crescent Street Waltham MA United States 02453
IPO Date
Sep 9, 2026
Business
Korsana Biosciences, Inc. is a biotechnology company focused on discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, with an emphasis on Alzheimer’s disease. Founded in 2024 and headquartered in Waltham, Massachusetts, the company operates in the United States and is advancing its pipeline through its proprietary THETA-enabled antibody engineering approach. Its lead product candidate is KRSA-028, a next-generation, shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer’s disease; the program is designed to improve amyloid plaque clearance, limit amyloid-related imaging abnormalities and hematologic adverse events, and support low-volume subcutaneous administration. Korsana’s development efforts include preclinical and discovery-stage work around neurodegenerative disease therapeutics, and its work with KRSA-028 was originally discovered in partnership with Paragon Therapeutics, Inc. Korsana also offers a pipeline of potential best-in-class therapeutics for neurodegenerative disorders under its THETA platform. In February 2026, the company emerged from stealth with $175 million in funding, including a prior $150 million Series A financing and an earlier seed round, to accelerate development of KRSA-028 toward clinical testing. In September 2026, Korsana completed its merger with Cyclerion Therapeutics, Inc. and a previously announced $380 million private placement, creating the combined public company now trading on Nasdaq under the ticker KRSA. In August 2026, the company strengthened its leadership team with the appointments of a Chief Medical Officer, a Chief Technical Officer, and a new Board member as it prepared for the transaction and continued advancing its neurodegenerative disease pipeline.

Company News

  • Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • Korsana Biosciences to Participate in Upcoming Investor Conferences

  • Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

  • Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?

  • SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

  • CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

  • Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

  • Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

  • Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript

  • Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

  • Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

  • Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

  • Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)

  • Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

  • Critical Contrast: Cyclerion Therapeutics (NASDAQ:CYCN) versus Response Genetics (OTCMKTS:RGDXQ)

  • Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

  • Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

  • Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

  • Regina Graul, Ph.D., Promoted to Chief Executive Officer

  • Cyclerion Appoints Regina Graul, Ph.D., as President